Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.

Impinj (PI - Get Report) : In his "Know Your IPO" segment, Cramer cycled back to Impinj, which came public in late July at $14 a share but has since rocketed to over $34 today, just two months later.

Impinj manufactures RFID technology that helps companies keep track of their inventory wirelessly and connect to our emerging Internet of things. Based on the company's estimates, 5.3 billion items were tagged with RFID tags last year, a number that is expected to balloon to 20 billion by 2020.

Impinj has applications in many areas, from retail to healthcare to automotive. Even airports can use Impinj technology to help track luggage.

When the company reported earnings at the end of August, it delivered an 8-cents-a-share earnings beat on a 36% rise in revenues with robust guidance to boot. However, Cramer cautioned Impinj is a small company in new markets, which makes it speculative. Shares are also trading at a lofty five times sales.

That said, Cramer noted that on a marketwise pullback, Impinj is the type of company investors should be seeking.

Charles River Labs (CRL - Get Report) : For his "Executive Decision" segment, Cramer sat down with Jim Foster, chairman, president and CEO of Charles River Labs, the contract research company helping biotech and big pharma get their breakthrough drugs to market.

Foster explained that Charles River's growing portfolio of research services help drugmakers make better go/no-go decisions quicker and help get safer drugs to market. No matter what the political environment may be for drugmakers, Foster said the capital markets are always willing to pay for innovation.

On such innovation Charles River is working on is humanized mice, which are lab mice that more accurately predict how drugs will respond in humans. Since mice have shorter lifespans, how those drugs respond over time. It's all about getting better information quicker, Foster said.

When asked about the advances being made for diseases like cancer, Foster said the research community is making enormous progress and he expects to see great strides being made over the next decade.

To read a full recap of "Mad Money" on CNBC, click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had no position in stocks mentioned.